Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
<p>Supplementary Table S3. Summary of other trial results for recurrent glioblastoma.</p>
সংরক্ষণ করুন:
| প্রধান লেখক: | |
|---|---|
| অন্যান্য লেখক: | , , , , , , , , |
| প্রকাশিত: |
2025
|
| বিষয়গুলি: | |
| ট্যাগগুলো: |
ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|
| _version_ | 1849927631942713344 |
|---|---|
| author | Qingsheng Xu (17078830) |
| author2 | Kaiyuan Huang (17078833) Xiangqi Meng (17078836) Yuxiang Weng (17078839) Luyuan Zhang (17078842) Linghao Bu (17078845) Xiujue Zheng (17078848) Jinquan Cai (17078851) Renya Zhan (17078854) Qun Chen (17078857) |
| author2_role | author author author author author author author author author |
| author_facet | Qingsheng Xu (17078830) Kaiyuan Huang (17078833) Xiangqi Meng (17078836) Yuxiang Weng (17078839) Luyuan Zhang (17078842) Linghao Bu (17078845) Xiujue Zheng (17078848) Jinquan Cai (17078851) Renya Zhan (17078854) Qun Chen (17078857) |
| author_role | author |
| dc.creator.none.fl_str_mv | Qingsheng Xu (17078830) Kaiyuan Huang (17078833) Xiangqi Meng (17078836) Yuxiang Weng (17078839) Luyuan Zhang (17078842) Linghao Bu (17078845) Xiujue Zheng (17078848) Jinquan Cai (17078851) Renya Zhan (17078854) Qun Chen (17078857) |
| dc.date.none.fl_str_mv | 2025-11-25T13:30:47Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30709542 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Supplementary_Table_S3_from_Safety_and_Efficacy_of_Anlotinib_Hydrochloride_Plus_Temozolomide_in_Patients_with_Recurrent_Glioblastoma/30709542 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine |
| dc.title.none.fl_str_mv | Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Supplementary Table S3. Summary of other trial results for recurrent glioblastoma.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_8a377453b8e52eaac476820a5539d792 |
| identifier_str_mv | 10.1158/1078-0432.30709542 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30709542 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent GlioblastomaQingsheng Xu (17078830)Kaiyuan Huang (17078833)Xiangqi Meng (17078836)Yuxiang Weng (17078839)Luyuan Zhang (17078842)Linghao Bu (17078845)Xiujue Zheng (17078848)Jinquan Cai (17078851)Renya Zhan (17078854)Qun Chen (17078857)CancerClinical Research and TrialsClinical Trial ResultsPhase II clinical trialsCNS CancersGliomas, GlioblastomasPrecision Medicine<p>Supplementary Table S3. Summary of other trial results for recurrent glioblastoma.</p>2025-11-25T13:30:47ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1158/1078-0432.30709542https://figshare.com/articles/dataset/Supplementary_Table_S3_from_Safety_and_Efficacy_of_Anlotinib_Hydrochloride_Plus_Temozolomide_in_Patients_with_Recurrent_Glioblastoma/30709542CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307095422025-11-25T13:30:47Z |
| spellingShingle | Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma Qingsheng Xu (17078830) Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine |
| status_str | publishedVersion |
| title | Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| title_full | Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| title_fullStr | Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| title_full_unstemmed | Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| title_short | Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| title_sort | Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma |
| topic | Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine |